6,7-Dihydrothieno[3,2-d]pyrimidine for the Treatment of Inflammatory Diseases

A medicament composition comprising

• A) one or more compounds of formula I,
• wherein
• X denotes SO;
• R1 denotes H, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C6-10-aryl, C6-10-aryl-C1-6-alkylene or C5-10-heteroaryl-C1-6-alkylene
• R2 is H or a group selected from among C1-10-alkyl, C2-6-alkenyl and C2-6-alkynyl, which may optionally be substituted by halogen and which may optionally be substituted by one or more groups selected from among OR2.1, COOR2.1, CONR2.2R2.3, SR2.1, C6-10-aryl, a mono- or bicyclic C3-10-heterocycle, a mono- or bicyclic C5-10-heteroaryl, a mono- or bicyclic C3-10-cycloalkyl, CH2—NR2.2R2.3 and NR2.2R2.3, which may in turn optionally be substituted by one or more groups selected from among OH, halogen, OR2.1, oxo, C1-6-alkyl, C6-10-aryl, COOR2.1, CH2—NR2.2R2.3 and NR2.2R2.3,
• wherein R2.1 is H or a group selected from among C1-6-alkyl, C1-6-alkanol, C1-3-haloalkyl, mono- or bicyclic C3-10-cycloalkyl, C6-10-aryl-C1-6-alkylene, mono- or bicyclic C5-10-heteroaryl-C1-6-alkylene, C3-10-heterocycle-C1-6-alkylene, C3-10-cycloalkyl-C1-6-alkylene, a mono- or bicyclic C6-10-aryl, a mono- or bicyclic C5-10-heteroaryl and a mono- or bicyclic, saturated or unsaturated heterocycle, which may optionally be substituted by one or more groups selected from among OH, halogen, C1-6-alkyl and C6-10-aryl,
• while R2.2 and R2.3 independently of one another are H or a group selected from among halogen, C1-6-alkyl, mono- or bicyclic C3-10-cycloalkyl, C6-10-aryl-C1-6alkylene, C5-10-heteroaryl-C1-6-alkylene, mono- or bicyclic C6-10-aryl, mono- or bicyclic C3-10-heterocycle, mono- or bicyclic C5-10-heteroaryl, CO—NH2, CO—NHCH3, CO—N(CH3)2, SO2(C1-C2-alkyl), CO—R2.1 and COOR2.1, which may optionally be substituted by one or more groups selected from among OH, halogen, C1-6-alkyl, C6-10-aryl and COOR2.1,
• or R2 denotes a mono- or polycyclic C3-10-cycloalkyl, which may optionally be bridged by one or more C1-3-alkyl groups and which may optionally be substituted by a group selected from among branched or unbranched C1-6-alkanol, OR2.1, COOR2.1 SO2NR2.2R2.3, C3-10-heterocycle, C6-10-aryl, C1-6-alkyl, C6-10-aryl-C1-6-alkylene, C5-10-heteroaryl-C1-6alkylene, mono- or bicyclic C3-10-cycloalkyl and NR2.2R2.3, which may optionally be substituted by one or more groups selected from among OH, OR2.1, oxo, halogen, C1-6-alkyl, C6-10-aryl and NR2.2R2.3,
• or R2 denotes a mono- or polycyclic C6-10-aryl, which may optionally be substituted by OH, SH or halogen or by one or more groups selected from among OR2.1, COOR2.1 NR2.2R2.3, CH2—NR2.2R2.3, C3-10-cycloalkyl, C3-10-heterocycle, C1-6-alkyl, C6-10-aryl-C1-6-alkylene, C3-10 heterocycle-C1-6-alkylene, C5-10-heteroaryl-C1-6-alkylene, C6-10-aryl, SO2—CH3, SO2—CH2CH3 and SO2—NR2.2R2.3, which may in turn optionally be substituted by one or more groups selected from among OH, OR2.1, oxo, halogen, C1-6-alkyl, C6-10-aryl and NR2.2R2.3,
• or R2 denotes a group selected from among mono- or bicyclic, saturated or unsaturated C3-10-heterocycle and a mono- or bicyclic C5-10-heteroaryl, which includes 1 to 4 heteroatoms selected from among S, O and N and optionally by one or more groups selected from among halogen, OH, oxo and SH or by one or more groups selected from among OR2.1, SR2.1, COOR2.1, COR2.1, C1-6-alkanol, C3-10-cycloalkyl, C6-10-aryl, C1-6-alkyl, C6-10-aryl-C1-6-alkylene, C5-10-heteroaryl-C1-6-alkylene, C5-10-heterocycle, C5-10-heteroaryl, C1-6-alkanol and NR2.2R2.3, which may in turn optionally be substituted by one or more groups selected from among OH, OR2.1, oxo, halogen, C1-6-alkyl, C6-10-aryl and NR2.2R2.3,
• or wherein NR1R2 together denote a heterocyclic C4-7 ring, which may optionally be bridged, which contains 1, 2 or 3 heteroatoms selected from among N, O and S and which may optionally be substituted by one or more groups selected from among OH, OR2.1, C1-6-alkanol, oxo, halogen, C1-6-alkyl, C6-10-aryl, COOR2.1, CH2—NR2.2—COO—R2.1, CH2—NR2.2—CO—R2.1, CH2—NR2.2—CO—CH2—NR2.2R2.3, CH2—NR2.2—SO2—C1-3-alkyl, CH2—NR2.2—SO2—NR2.2R2.3, CH2—NR2.2—CO—NR2.2R2.3, CO—NR2.2R2.3, CH2—NR2.2R2.3 and NR2.2R2.3,
• and wherein
• R3 is selected from among fluorine, chlorine, bromine, iodine, hydroxy, SO2—CH3, COOR2.1, nitrile group and C3-10-heterocycle-C1-6-alkylene, wherein the C3-10-heterocycle may be mono- or bicyclic and may optionally be substituted by a group selected from among OH, halogen, oxo, C1-6-alkyl and C6-10-aryl,
• or
• is a group selected from among C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C6-10-aryl;
• C6-10-aryl-C1-6-alkylene, C5-10-heteroaryl-C1-6-alkylene, C3-10-heterocycle and C3-10-cycloalkyl, which may optionally be substituted by a group selected from among OH, halogen, oxo, C1-6-alkyl and C6-10-aryl,
• or wherein
• R3 denotes the group —CO—NR3.1R3.2,
• wherein R3.1 and R3.2 independently of one another are H or groups selected from among C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C6-10-aryl;
• C6-10-aryl-C1-6-alkylene, C5-10-heteroaryl-C1-6-alkylene, C5-10-heteroaryl-C1-6-alkynylene, C5-10-heteroaryl-C1-6-alkenylene, mono- or bicyclic, C3-10-heterocycle, C3-10 heterocycle-C1-6-alkylene and mono- or bicyclic C5-10-heteroaryl, wherein the group in each case may optionally be substituted by one or more groups selected from among OH, oxo, halogen, C1-6-alkyl and O—C1-6-alkyl,
• or wherein
• R3 denotes the group —NR3.3—CO—R3.4,
• wherein R3.3 is H or a group selected from among C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C6-10-aryl;
• C6-10-aryl-C1-6-alkylene, C5-10-heteroaryl-C1-6-alkylene, C3-10-heterocycle and a C5-10-heteroaryl, which may optionally be substituted by one or more groups selected from among OH, OR2.1, oxo, NH2, NR2.2R2.3, halogen, C1-6-alkyl and C6-10-aryl, and
• wherein R3.4 is H or a group selected from among C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkanol, OR2.1, CH2—O—CO—C1-6-alkyl, CH2—NR2.2R2.3, NR2.2R2.3, C6-10-aryl;
• C6-10-aryl-C1-6-alkylene, C5-10-heteroaryl-C1-6-alkylene, mono- or bicyclic, saturated, partially saturated or unsaturated C3-10-heterocycle with 1, 2 or 3 heteroatoms selected from among S, O and N and a mono- or bicyclic C5-10-heteroaryl with 1, 2 or 3 heteroatoms selected from among S, O and N, which may optionally be substituted by one or more groups selected from among OH, OR2.1, oxo, NH2, NR2.2R2.3, halogen, C1-6-alkyl and C6-10-aryl,
• or wherein
• R3 denotes an optionally mono- or di-N-substituted sulphonamide group SO2—NR3.5R3.6,
• wherein R3.5 and R3.6 denote independently of one another C1-6-alkyl or C6-10-aryl,
• and
• B) one or more compounds as further active agents selected from the group consisting of:
• betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, dopamine agonists, CCR3-inhibitors, PAF-antagonists, MPR4-Inhibitors, iNOS-Inhibitors, SYK-Inhibitors and double or triple combinations thereof.